Back to search

Duquesne

DELIVERY OF MITOCHONDRIA-CONTAINING ENGINEERED EXTRACELLULAR VESICLES TO THE BLOOD-BRAIN BARRIER FOR ISCHEMIC STROKE THERAPY

Abstract

dc:description.abstract

Ischemic stroke is the second leading cause of death worldwide, and the lack of effective treatment options is an unmet clinical need for stroke survivors. Ischemic stroke-induced oxygen-glucose deprivation (OGD) in the affected brain tissue leads to mitochondrial dysfunction and adenosine triphosphate (ATP) depletion in the brain endothelial cells (BECs) lining the blood-brain barrier (BBB). ATP deprivation in the BECs dysregulates actin cytoskeleton dynamics, resulting in BBB breakdown. Restoration of blood flow (i.e., reperfusion) upon the first-line stroke treatment further leads to BBB breakdown and widens the paracellular spaces between BECs. Subsequent reperfusion infiltrates harmful blood toxins and immune cells into the brain, resulting in severe neurovascular injuries and cognitive impairments. Therefore, enhancing BEC mitochondrial functions and protecting its structural integrity is a promising approach to alleviating ischemia/reperfusion-mediated neurovascular injury. Mitochondrial component-containing extracellular vesicles (EVs), including exosomes (EXOs) and microvesicles (MVs), are intriguing and promising strategies for delivering mitochondria to the target site. EV-mediated transfer of mitochondrial components to the injured cells has shown increased recipient cell ATP levels, oxidative phosphorylation, mitochondrial biogenesis, and cell survival in various cell culture studies and preclinical disease models. In addition to the innate mitochondrial cargo, EVs can be engineered to enrich innate mitochondrial components as well as to load exogenous therapeutic nucleic acids or proteins that can protect BBB integrity post-ischemic stroke. Engineered EVs containing an enriched mitochondrial load may be a more potent treatment strategy to increase BEC metabolic functions compared to naïve EVs. Published studies have shown that brain-derived neurotrophic factor (BDNF) released from cerebral endothelial cells enhance post-stroke neuronal cell viability due to its neuroprotective effects. Preclinical studies have demonstrated that overexpression of 27 kDa heat shock protein (HSP27) in brain BEC inhibits actin polymerization and restores BBB tight junctions, eliciting long-lasting protection against stroke-induced BBB disruption. Hence, engineering mitochondria-containing EVs with exogenous plasmid BDNF or HSP27 could enhance EV-mediated BBB and neurovascular protection post-ischemic stroke. The central hypothesis of this work is that delivery of mitochondria-containing naïve EVs or BDNF/HSP27-loaded engineered EVs to the injured BECs could increase cellular ATP levels, mitochondrial respiration, and blood-brain barrier integrity, which will ultimately decrease mouse brain infarct volume post-ischemic stroke. This dissertation tested this hypothesis via three primary aims: (1) investigating mitochondria-contacting naïve EV-mediated decrease in mouse brain infarct volume post-stroke, (2) evaluating whether enriched mitochondrial load (mito-EVs) or plasmid BDNF-loaded EVs (pBDNE-EVs) could outperform naïve EV’s mitochondrial functionality, and (3) investigating if HSP27-loaded EVs (HSP27-EVs) could protect BBB integrity during ischemia/reperfusion injury. The results showed that intravenously injected BEC-derived MVs showed a significant reduction in mouse brain infarct volume and significantly improved neurological functions in a mouse model of ischemic stroke. Mito-MVs significantly increased recipient ischemic BEC ATP levels compared to naïve MVs. The data showed the capability of EVs to load an exogenous plasmid DNA and pBDNF-EV-mediated increases in intracellular ATP levels in recipient BECs. Lastly, HSP27-EVs significantly reduced ischemia-induced paracellular permeability of small and large tracer molecules across primary BEC monolayers. In conclusion, mitochondria-containing naïve and engineered MVs demonstrate potential to restore ischemic BBB metabolic functions and structural integrity to improve post-stroke outcomes.

Degree

thesis:*
Name thesis:degree_name
PhD
Level thesis:degree_level
One-year Embargo
Discipline thesis:degree_discipline
Pharmaceutics

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Dave, Kandarp
Contributors dc:contributor
  • Devika S Manickam
  • Rehana K. Leak
  • Wilson Meng
  • R. Anne Stetler
  • Peter L. D. Wildfong

Subjects

dc:subject × 9

Rights

Language dc:language
English

Identifiers

dc:identifier.*
Repository record dc:identifier
https://dsc.duq.edu/etd/2372

Chain of custody

source
Harvested from
Duquesne
Base URL
dsc.duq.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Dave, Kandarp. DELIVERY OF MITOCHONDRIA-CONTAINING ENGINEERED EXTRACELLULAR VESICLES TO THE BLOOD-BRAIN BARRIER FOR ISCHEMIC STROKE THERAPY. One-year Embargo thesis, https://dsc.duq.edu/etd/2372